Qinquan Tan
Dongguan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II study.
Journal: The oncologist
Published: March 18, 2026
A Hybrid Protein-Oxygen Nanomedicine Overcomes Osimertinib Resistance in NSCLC via HIF-1α/VEGF/EGFR Inhibition.
Journal: International journal of nanomedicine
Published: March 31, 2025
Clinical Therapy: HAIC Combined with Tyrosine Kinase Inhibitors and Programmed Cell Death Protein-1 Inhibitors versus HAIC Alone for Unresectable Hepatocellular Carcinoma.
Journal: Journal of hepatocellular carcinoma
Published: May 02, 2024
Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
Journal: Journal of immunology research
Published: November 09, 2021
Ginsenoside Rg3 attenuates the osimertinib resistance by reducing the stemness of non-small cell lung cancer cells.
Journal: Environmental toxicology
Published: October 26, 2019
Identification of the BRAF V600E mutation in a patient with sclerosing pneumocytoma: A case report.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 03, 2019
Antibiotic use is a negative predictor of the efficacy and toxicity of epidermal growth factor receptor-targeted therapy in advanced non-small cell lung cancer.
Journal: Oncology letters
Published: August 25, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026